Aardvark Therapeutics Files 8-K
Ticker: AARD · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1774857
| Field | Detail |
|---|---|
| Company | Aardvark Therapeutics, INC. (AARD) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, company-update
TL;DR
Aardvark Therapeutics filed an 8-K on 12/10/25, likely with financial updates.
AI Summary
On December 10, 2025, Aardvark Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating potential updates or disclosures related to the company's financial status and other significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signifies that Aardvark Therapeutics, Inc. is providing material updates to the SEC, which could impact investor understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific operational or financial risks.
Key Players & Entities
- Aardvark Therapeutics, Inc. (company) — Registrant
- December 10, 2025 (date) — Date of Report
- 001-42513 (other) — SEC File Number
- 821606367 (other) — IRS Employer Identification No.
- 4370 La Jolla Village Drive, Suite 1050 (address) — Principal Executive Offices
- San Diego, California (location) — Principal Executive Offices City and State
- 92122 (zip_code) — Principal Executive Offices Zip Code
- (858) 225-7696 (phone_number) — Registrant's Telephone Number
FAQ
What specific "Other Events" are being reported by Aardvark Therapeutics, Inc. in this 8-K filing?
The provided excerpt does not specify the details of the "Other Events" beyond listing it as an item information category.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is December 10, 2025.
What is Aardvark Therapeutics, Inc.'s SEC File Number?
Aardvark Therapeutics, Inc.'s SEC File Number is 001-42513.
Where are Aardvark Therapeutics, Inc.'s principal executive offices located?
Aardvark Therapeutics, Inc.'s principal executive offices are located at 4370 La Jolla Village Drive, Suite 1050, San Diego, California, 92122.
What is the SIC code for Aardvark Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Aardvark Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-12-10 16:54:58
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share AARD The Nasdaq Stock Mar
Filing Documents
- ck0001774857-20251210.htm (8-K) — 46KB
- ck0001774857-ex99_1.htm (EX-99.1) — 25KB
- img213560662_0.jpg (GRAPHIC) — 21KB
- 0001193125-25-314364.txt ( ) — 213KB
- ck0001774857-20251210.xsd (EX-101.SCH) — 25KB
- ck0001774857-20251210_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 10, 2025, Aardvark Therapeutics, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in Australia in the Company's Phase 3 HERO pivotal clinical trial assessing ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi syndrome. Additionally, regulatory clearance for enrollment by clinical trial sites in Canada and the United Kingdom participating in the HERO trial has also been received. At this time, the Company anticipates that it will not need to activate previously planned sites in the EU to fully enroll the HERO trial and meet its anticipated timeline for topline data readout in the third quarter of 2026. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AARDVARK THERAPEUTICS, INC. Date: December 10, 2025 By: /s/ Tien-Li Lee, M.D. Tien-Li Lee, M.D. Chief Executive Officer